The farnesoid X receptor (FXR), also known as NR1H4, is a nuclear receptor that functions as the primary bile acid sensor in the body. Activated by bile acids—especially chenodeoxycholic acid (CDCA)—FXR regulates bile acid synthesis, cholesterol metabolism, glucose homeostasis, and intestinal barrier integrity.
Because gut bacteria determine which bile acids are present through deconjugation and transformation, the microbiome effectively controls FXR signaling, making this receptor a critical node in the gut-liver axis.
Evidence map1 cited passagesInspect provenance +
FXR agonist CDCA reduces blood pressure in spontaneously hypertensive rat models through iNOS expression, connecting bile acid sensing to vascular regulation. This positions FXR at the intersection of gut microbiome composition, bile acid metabolism, and cardiovascular disease risk.
Contents
1. Bile Acid Activation2. Metabolic Functions3. Cardiovascular Relevance4. Microbiome Disruption of FXR5. Cross-ReferencesBile Acid Activation#
Primary bile acids synthesized in the liver (cholic acid, CDCA) are conjugated with taurine or glycine and secreted into the duodenum.
Gut bacteria expressing bile salt hydrolase (BSH)—including Blautia, Bacteroides fragilis, Lactobacillus, and Bifidobacterium—deconjugate these bile acids, enabling further microbial transformation into secondary bile acids (deoxycholic acid, lithocholic acid).
FXR responds differently to these metabolites. CDCA—Most potent natural FXR agonist; drives protective anti-inflammatory signaling. Cholic acid—Moderate agonist.
DCA, LCA—Weak FXR agonists; instead preferentially activate TGR5, which can drive pro-inflammatory IL-23 production.
Dysbiosis that shifts bile acid composition from primary toward secondary bile acids therefore redirects signaling from FXR-dominant (protective) to TGR5-dominant (inflammatory)—a mechanism implicated in Colorectal Cancer, Type 2 Diabetes, and hepatic steatosis.
Metabolic Functions#
FXR activation orchestrates a broad metabolic program. Bile acid homeostasis: FXR induces FGF15/19 in the ileum, which travels to the liver and suppresses CYP7A1 (the rate-limiting enzyme in bile acid synthesis), preventing toxic bile acid accumulation.
Glucose metabolism: Intestinal FXR activation improves insulin sensitivity and suppresses hepatic gluconeogenesis. Lipid metabolism: FXR reduces hepatic triglyceride synthesis and promotes fatty acid oxidation. Barrier integrity: FXR maintains tight junction protein expression and reduces intestinal permeability.
Immune regulation: FXR activation in intestinal immune cells suppresses NF-kB signaling, reducing inflammatory cytokine production.
Cardiovascular Relevance#
FXR agonist CDCA reduces blood pressure in spontaneously hypertensive rat models through iNOS expression, connecting bile acid sensing to vascular regulation.[1]Bile acids at the cross-roads of gut microbiome-host cardiometabolic interactionsPaul M. Ryan, Catherine Stanton, Noel M. Caplice · 2017Open reference 1 ↓ This positions FXR at the intersection of Gut Microbiome composition, bile acid metabolism, and cardiovascular disease risk.
Microbiome Disruption of FXR#
When dysbiosis depletes BSH-expressing commensals, conjugated bile acids accumulate and FXR activation is reduced. Specific patterns include.
Collinsella enrichment alters bile acid profiles, reducing hepatic bile acid synthesis via disrupted FXR signaling and promoting lipid accumulation. Clostridium symbiosum enrichment shifts the bile acid pool toward secondary bile acids with weak FXR but strong TGR5 activity.
Odoribacter and Blautia BSH activity supports FXR-activating bile acid pools; their depletion impairs FXR signaling.
Cross-References#
- Bile Acid Metabolism—upstream process that determines FXR ligand availability
- Blautia—BSH-expressing genus that modulates FXR signaling
- Collinsella—disrupts FXR via altered bile acid profiles
- Type 2 Diabetes—FXR dysfunction contributes to insulin resistance
- Hypertension—FXR agonists reduce blood pressure via iNOS
References 9
Numbered by first appearance in the article, then reconciled with its declared source list.
- 1
Paul M. Ryan, Catherine Stanton, Noel M. Caplice (2017). Bile acids at the cross-roads of gut microbiome-host cardiometabolic interactions. Diabetology and Metabolic Syndrome.
- 2
Melika Shirdarreh, Yasamin Sadeghi, Tina Rahimi (2021). The Impact of Ketogenic Diet on Colorectal Cancer Progression and the Co-evolution of Gut Microbiota: A Research Protocol. URNCST Journal.
- 3
Tiffany L Weir, Daniel K Manter, Amy M Sheflin et al. (2013). Stool Microbiome and Metabolome Differences between Colorectal Cancer Patients and Healthy Adults. PLoS ONE.
- 4
Alexander C. Razavi, Kaitlin S. Potts, Tanika N. Kelly et al. (2019). Sex, gut microbiome, and cardiovascular disease risk. Biology of Sex Differences.
- 5
Negin Kazemian, Morteza Mahmoudi, Frank Halperin et al. (2020). Gut Microbiota and Cardiovascular Disease: Opportunities and Challenges. Microbiome.
- 6
Hao Zhou, Juan Felipe Beltran, Ilana Lauren Brito (2022). Host-microbiome protein-protein interactions capture disease-relevant pathways. Genome Biology.
- 7
Xinjian Xu, Ji Lv, Fang Guo et al. (2020). Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway. Frontiers in Microbiology.
- 8
★Sweta Ghosh, Syam P. Nukavarpu, Venkatakrishna Rao Jala (2024). Effects of Heavy Metals on Gut Barrier Integrity and Gut Microbiota. Microbiota and Host.
- 9
Allison M. Plummer, Yvette L. Matos, Henry C. Lin et al. (2023). Plummer et al 2023 — Gut-Brain Pathogenesis of Post-Acute COVID-19 Neurocognitive Symptoms. Frontiers in Neuroscience.
Article network
Mentioned here 14
Pages linking here 5
Connect the evidence
Publicly readable discussion by ORCID-authenticated researchers. Questions, interpretation, methods, corrections, and new evidence stay attached to this record.
No discussion yet. Start with a precise question or a source-backed observation.
Activity and accepted changes
Accepted researcher context, editorial status, public discussion, and upstream Git revisions are shown together. Pending, declined, and withdrawn proposals remain private.
- published revision
Backfill gut microbiome concept links
Karen Pendergrass · +1 −1
Inspect exact Git diff ↗ - published revision
Complete corpus-wide Dysbiosis linking
Karen Pendergrass · +1 −1
Inspect exact Git diff ↗ - published revision
Complete Tight junctions contextual coverage
Karen Pendergrass · +1 −1
Inspect exact Git diff ↗ - published revision
massive wiki expansion: 149 stubs fixed, 100+ new pages, Rule 15 scan, keystone papers
WikiBiome Deploy Bot · +23 −18
Inspect exact Git diff ↗ - published revision
maintenance: 409 source fixes, 34 entity updates, 17 concept updates, 30 analysis outputs
WikiBiome Deploy Bot · +72 −0
Inspect exact Git diff ↗